Today: 28 January 2026
Subscribe
Browse Category

Cancer Research News 26 September 2025 - 20 October 2025

Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results

Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results

Stock Soars on Positive Trial News Celcuity’s stock price skyrocketed on October 20, 2025 after the Minneapolis-based biotech reported game-changing clinical trial results. Shares jumped from around $52 to as high as $78–$81 intraday Marketbeat, an approximately 40–50% single-day leap, before settling near a record high close. This surge marked a new 52-week high of $81.56 Marketbeat and lifted Celcuity’s…
20 October 2025
····
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (NASDAQ: SLS) stock has surged roughly 100% year-to-date, closing around $2.14 on Oct. 17, 2025 ts2.tech ts2.tech (versus a 52-week low of $0.77). In after-hours trading on Oct. 17 it spiked another +38%, briefly touching a new 52-week high ts2.tech. Big investors are piling in: BlackRock disclosed a 5.4% stake (~5.7M shares) in SLS on Oct. 18…
20 October 2025
····
Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

SMMT Stock’s Wild Ride in 2025 Summit Therapeutics’ share price has been on a roller-coaster ride this year. After a steady climb through late summer, SMMT spiked above $25 intraday in mid-October, then pulled back to end last week just under $21 ts2.tech. The stock fell 4.5% on Friday, Oct. 17 alone ts2.tech as traders braced for the upcoming data…
20 October 2025
···
Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

What to Know Before Markets Open on October 20, 2025 SMMT’s Wild Stock Ride in 2025 Summit Therapeutics’ share price has experienced extreme swings this year. After a steady climb through late summer, SMMT spiked to an intraday high above $25 on Oct. 13, 2025, before pulling back to end the week just under $21 Stockanalysis. The stock fell 4.5%…
19 October 2025
···
GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test Samsung Tradingview. GRAIL, Inc. is focused on early cancer detection – its mission is “to detect cancer early when it can be cured” Samsung. The company’s Galleri test analyzes tumor DNA in blood to screen for dozens of cancers in asymptomatic…
18 October 2025
····
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

Samsung Partnership Sparks Stock Surge GRAIL, Inc. (NASDAQ: GRAL) shares soared to record highs this week after the company announced a strategic collaboration with Samsung. On October 16, GRAIL revealed a binding agreement in which Samsung C&T and Samsung Electronics will invest $110 million into GRAIL at $70.05 per share ts2.tech. In return, Samsung C&T gains exclusive rights to distribute GRAIL’s…
17 October 2025
···
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

Strategic Samsung Partnership GRAIL’s shares surged after it announced a deal on Oct. 16 to partner with Samsung in Asia. The binding Letter of Intent involves Samsung C&T and Samsung Electronics investing $110 million in GRAIL at $70.05 per share, with Samsung C&T to distribute the Galleri multi-cancer screening test in South Korea Investing Prnewswire. This collaboration gives Samsung “a strong…
16 October 2025
···
Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Recent Clinical Developments and Pipeline Updates Theriva Biologics – a Rockville, MD-based clinical-stage biotech – has made headlines with promising cancer trial results. On October 13, 2025, the company announced that expanded data from its VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma will be presented at the ESMO 2025 Congress on Oct. 20 ts2.tech. In this trial, patients…
16 October 2025
···
Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Recent News and Pipeline Developments Theriva Biologics (NYSE American: TOVX) has been in the news for its upcoming conference presentations and strong trial data. On October 13, 2025 the company announced that expanded data from the VIRAGE Phase 2b trial (metastatic pancreatic cancer) will be presented at the ESMO 2025 Congress on October 20 Sec. In VIRAGE, the oncolytic adenovirus…
15 October 2025
····
Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion’s stock jump in mid-October comes as the company lines up important clinical updates and validates its AI-driven vaccine technology. On Oct 13, Evaxion announced it will present two-year data from its Phase 2 trial of EVX-01 (a personalized cancer vaccine for advanced melanoma) at the ESMO Congress in Berlin Globenewswire. The October presentation (oral session Oct 17, webinar Oct 22) will cover…
15 October 2025
···
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Analysis: GRAIL’s stock performance reflects a wave of optimism about its Galleri cancer-screening test and pending trial results. In late September it broke out to new highs, aided by momentum and positive chatter (e.g. a StocksToTrade report noted a 17.93% jump on Sept 29 as MCED excitement grew Stockstotrade). The company itself is pushing the narrative: GRAIL President Dr. Josh…
3 October 2025
···
PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

Key facts (25–26 Sept 2025) What happened—and why it mattered UnitedHealthcare coverage win. On Sept. 25, Plus Therapeutics announced that UnitedHealthcare Insurance Company (UNH) granted national coverage for its CNSide® CSF Tumor Cell Enumeration LDT for metastatic CNS cancer, effective Sept. 15. The deal potentially opens access to more than 51 million members nationwide and positions CNSide as a covered…
26 September 2025
···
1 … 3 4 5

Stock Market Today

  • S&P 500 Hits 7,000 as Market Awaits Fed Guidance and Big Tech Earnings
    January 28, 2026, 3:23 PM EST. US stocks fluctuated Wednesday after the Federal Reserve held interest rates steady at 3.5% to 3.75% in a 10-2 vote. The S&P 500 briefly surpassed the 7,000 threshold for the first time but closed near flat after a record earlier. Fed Chair Jerome Powell's remarks are now key for potential rate cuts, with markets pricing in two 25 basis-point cuts by end-2026. Political tensions surround the Fed amid a Trump-led criminal probe into Powell and speculation over his successor. Tech stocks gained amid optimism from ASML's chip orders fueling AI growth, pushing Nvidia and TSMC higher. Attention turns to earnings from Microsoft, Meta Platforms, Tesla, and Apple, setting the tone for the tech sector.
Go toTop